Are you Dr. Lidofsky?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 64 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
111 Colchester Ave
Burlington, VT 05401Phone+1 802-847-8865Fax+1 802-847-7082
Summary
- Dr. Steven Lidofsky, MD is a gastroenterologist in Burlington, Vermont. He is currently licensed to practice medicine in Vermont, New York, and California. He is affiliated with University of Vermont Medical Center and is a Professor at University of Vermont College of Medicine.
Education & Training
- University of California (San Francisco)Fellowship, Gastroenterology, 1986 - 1990
- University of ColoradoResidency, Internal Medicine, 1982 - 1985
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1982
Certifications & Licensure
- CA State Medical License 1986 - Present
- VT State Medical License 1997 - 2026
- NY State Medical License 2022 - 2025
- CO State Medical License 1984 - 1987
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Transplant Hepatology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism Start of enrollment: 2011 Jul 01
Publications & Presentations
PubMed
- 49 citationsPeginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis CEdward L. Krawitt, Takamaru Ashikaga, Stuart R. Gordon, Nicholas Ferrentino, Mary Ann Ray
Journal of Hepatology. 2005-08-01 - 55 citationsScreening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility studyRichard Zubarik, Stuart R. Gordon, Steven D. Lidofsky, Scott R. Anderson, J. Marc Pipas
Gastrointestinal Endoscopy. 2011-07-01 - 169 citationsIntracranial pressure monitoring and liver transplantation for fulminant hepatic failureSteven D. Lidofsky, Nathan M. Bass, Marie Csete Prager, Denna E. Washington, A. E. Read
Hepatology. 1992-07-01
Grant Support
- Mechanisms Of Cell Volume Regulation In LiverNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2011
- Mechanisms Of Cell Volume Regulation In LiverNational Institute Of Diabetes And Digestive And Kidney Diseases2007
- Metformin For The Treatment Of Non-Alcoholic SteatohepatitisNational Center For Research Resources2004–2005
- Mechanism Of Cell Volume Regulation In LiverNational Institute Of Diabetes And Digestive And Kidney Diseases2001–2005
- Ionic Signaling Mechanisms In HepatocytesNational Institute Of Diabetes And Digestive And Kidney Diseases1997–2000
- Ionic Signaling Mechanisms In HepatocytesNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1997
- Mechanisms Of Ionic Signaling By Hepatic Growth FactorsNational Institute Of Diabetes And Digestive And Kidney Diseases1990–1994
- Regulation Of Cytosolic Calcium In HepatocytesNational Institute Of Diabetes And Digestive And Kidney Diseases1989